CytomX Therapeutics Inc
CytomX Therapeutics Inc (CTMX) Options Open Interest
CTMX options open interest is 20,701 contracts. The 2-week average daily volume is 877 contracts across the chain.
Read more
Monitoring CTMX open interest helps you see where real money is positioned on CytomX Therapeutics Inc's options and which strikes are attracting the most commitment from traders. CytomX Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor CTMX options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising CTMX options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect CytomX Therapeutics Inc to settle.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.
It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where CTMX open interest is concentrated. Our scanner maps CytomX Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade CytomX Therapeutics Inc's options open interest as the signal it is, not as an afterthought.
| 4.00 | — | 0.05 | 0.05 | 435% | +0.1362 | 816 |
| 3.00 | — | 0.25 | 0.25 | 456% | +0.4561 | 186 |
| 2.00 | 0.25 | 0.90 | 0.58 | 38% | +1.0000 | 20 |
| 5.00 | — | 0.05 | 0.05 | 601% | +0.1077 | 16 |
| 1.00 | 1.25 | 2.25 | 1.75 | 146% | +1.0000 | 0 |
| 4.00 | 1.20 | 1.60 | 1.40 | 643% | -0.7331 | 4,431 |
| 3.00 | 0.10 | 0.55 | 0.33 | 230% | -0.6735 | 6 |
| 1.00 | — | 0.05 | 0.05 | 1,000% | -0.0340 | 0 |
| 2.00 | — | 0.30 | 0.30 | 957% | -0.2063 | 0 |
| 5.00 | 1.80 | 2.80 | 2.30 | 630% | -0.8771 | 0 |
As of September 16, 2026
Follow the money
Track CTMX open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→